Clinical Trial Update: Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

This clinical trial update reports long-term safety data for dasatinib in patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2016-01-22